


APPROVED	G.S. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

1/13

FIG. 1A




08819669-034797

APPROVED	C.G. FIG.	
BY	CLASS	SUBCLASS
RAFTSMAN		

2/13


2627ED-6996T88D

FIG. 1B




3/13

FIG. 2



08819669-031797

FIG. 3



08819669-031797

5/13

FIG. 4

1	2	3	4	5	6	7
P1.HTR	P1.HTR	PO.HTR	L138.8A	P1.HTR	Liver DBA/2	Spleen DBA/2

P1A
probe a

P1A probe b

kb

2.6 →

1.5 →

1.2 →




β-actin probe




00019669-031797

FIG. 5



7/13

FIG. 6



262700 69967880

8/13

FIG. 7





FIG. 8

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 9

MAGE-3 /// CCTCCCCAGAGTCCCTCAGGGAGCCTCCagCCTcCCCACATACCATgAACTaCCCTCtctgGAGcCAATCCTaTGAGGacTCCAGCAaCCaaGAAGAGGAGG
 MAGE-2 // CCTCCCCACAGTCCTCAGGGAGCCTCCagCTTtctCgACTACCATCAACTaCACTCtcttgGAGaCAATCCgaTGAGGGcTCCAGCAaCCaaGAAGAGGAGG
 MAGE-1 / CCTCCCCAGAGTCCCTCAGGGAGCCTCCGCTTtCCACTACCATCAACtTCACTCGACAGAGGCAACCCAGTGAGGGTtCCAGCAGCCGtGAAGAGGAGG
 225 CHO-3
 325
 /// GGCCAAAGCACCTtcccTgaCC-TGGAGTCCgaGTTCCaaGCAGcAcTCAGTAGAAAGTGGCCcGagTtGGTtcaTTTTCTGCTCCTCAAgTATCGAGCCA
 // GGCCAAAGaAtgTtTcccgaCCTTGGAGTCCGAGTtCCaaGCAGcAATCAgTAGAAAGaTGGtTGAGtTGGTtcaTTTTCTGCTCCTCAAgTATCGAGCCA
 / GGCCAAAGcACCTCtTGTATCC-TGGAGTCCtTGTtCCGAGcAGTAATCACTAAAGAGTGGCTGATtTGGTtGGTtTtTCTGCTCCTCAAAATATCGAGCCA
 325
 /// GGGAGCCgGTCACAAAGGCAGAAATGCTGGgGAGTGTCTgTcggAAATtggcAGtAtTtCTTCTGTgTGATCTTCaGCAAAAGCtTccagTTCCTTGCAGCT
 // GGGAGCCgGTCACAAAGGCAGAAATGCTGGAGAGTGTCTcTCAGAAATtgcAGACTtCTTCCcGtGATCTTCaGCAAAAGCCTCCGAGTaCTTGCAGCT
 / GGGAGCCAGTCACAAAGGCAGAAATGCTGGAGAGTGTCTcTCAAAATtTACAGCACTGTtTCTGAGATCTTTCGGCAAAAGCCTCTGAGTCCCTTGCAGCT
 425
 525
 /// GGTCTTTGGCATcGAgcTGATGGAGTgGAGCCCATCGGCCACTtGTAcATCTTTGcCACCTGCCCTgGGcCTCTCTCCTAcGATGGCCCTGCTGGGTGACAAT
 // GGTCTTTGGCATcGAgGTGgTGGAGTgGtCCCCATCaGCCACTtGTAcATCTTTGTCACCTGCCCTgGGcCTCTCTCCTAcGATGGCCCTGCTGGGcGACAAAT
 / GGTCTTTGGCATtGACGTGAAGGAAGCAAGCAACCCACGGCCACTCTCTATGTCTGTCACTGTCTGTCACTGTCTCTCTATGATGGCTGTGGGTGATAAT
 525
 /// CAGATCATGCCCCAAGcCAGGCCCTCTGATAATCGTCTGGCCATaATCGCAAGaGAGGGCGaCtGTGCCCTTGAGAGaAAATCTGGGAGGAGCTGAGTG
 // CAGgTCATGCCCCAAGCAGAGGCCCTCTGATAATcGTC-TGGCCATaATCGCAATaGAGGGCGaCtGTGCCCTTGAGAGaAAATCTGGGAGGAGCTGAGTa
 / CAGATCATGCCCCAAGCAGGCCCTCTGATAATGTCTGTGTGATGCAATGGAGGGCGCCATGTCTCTGAGAGGAAATCTGGGAGGAGCTGAGTG
 625
 CHO-9

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

10/13

β -action

MAGE

PROBES

FIG. 10



MZ2-MEL.3.0
MZ2-MEL 1982
MZ2-MEL.2.2 E-
MZ2-PBL-PHA
Lung
Kidney



MZ2-MEL 3.0
MZ2-CTL 82/30
LB34-MEL
LB17-MEL
MI665/2-MEL
LB41-MEL
MI10221-MEL
MI13443-MEL
SK23-MEL
SK33-MEL

Other
melanomas



LB4-MEL
MI4024-MEL
MZ3-MEL
MZ5-MEL
SK29-MEL
LB31-COL
LS411-COL

Other
tumors



H209-SCLC
H345-SCLC
H510-SCLC
TT

08819669.03199

11/13

FIG. 11Expression of
antigen MZ2-E
after transfection**

		EXPRESSION OF MAGE GENE FAMILY				RECOGNITION BY ANI-E CTL		
		Northern blot probed with cross-reactive MAGE-1 probe*	cDNA-PCR product probed with oligonucleotide specific for:			tested by:		
			MAGE-1	MAGE-2	MAGE-3†	TNF release‡	Lysis§	
Cells of patient MZ2	melanoma cell line MZ2-MEL3.0	+	++++	++++	++++	+	+	
	tumor sample MZ2 (1982)	+	+++	+++	+++			
	antigen-loss variant MZ2-MEL2.2	+	-	+++	+++	-	-	
	CTL clone MZ2-CTL82/30	-	-	-	-			
	PHA-activated blood lymphocytes	-	-	-	-			
Normal tissues	Liver	-	-	-	-			
	Muscle	-	-	-	-			
	Skin	-	-	-	-			
	Lung	-	-	-	-			
	Brain	-	-	-	-			
	Kidney	-	-	-	-			
Melanoma cell lines of HLA-A1 patients	LB34-MEL	+	++	++++	++++	+	+-	
	MI6652-MEL	-	-	-	-	-	-	+
	MI10221-MEL	+	-	++	+++	-	-	+
	MI13443-MEL	+	+++	++++	++++	+	+	
	SK33-MEL	+	-	++++	++++	-	-	-
	SK23-MEL	+	-	++++	++++	-	-	+
Melanoma cell lines of other patients	LB17-MEL	+	+	++++	++++	-	-	-
	LB33-MEL	+	-	+++	+++	-	-	-
	LB4-MEL	-	-	-	-	-	-	
	LB41-MEL	-	-	-	-	-	-	
	MI4024-MEL	+	+++	++++	++++	-	-	
	SK29-MEL	-	-	-	-	-	-	
	MZ3-MEL	+	+	++++	++++	-	-	
	MZ5-MEL	+	-	++++	++++	-	-	
Melanoma tumor sample	BB5-MEL	+	+++	++	+++			
Other tumor cell lines	small cell lung cancer H209	+	-	++++	++++			
	small cell lung cancer H345	+	-	++++	++++			
	small cell lung cancer H510	+	-	++++	++++			
	small cell lung cancer LB11	+	+	++++	++++			
	bronchial squamous cell carcinoma LB37	+	-	-	+++			
	thyroid medullary carcinoma TT	+	++++	+++	++++			
	colon carcinoma LB31	+	-	+++	++++	-		
	colon carcinoma LS411	-	-	-	-			
Other tumor samples	chronic myeloid leukemia LLC5	-	-	-	-			
	acute myeloid leukemia TA	-	-	-	-			

* Data obtained in the conditions of figure 5.

† Data obtained as described in figure 6.

‡ TNF release by CTL 82/30 after stimulation with the tumor cells as described in (11).

§ Lysis of 51 Cr labelled target by CTL 82/30 in the conditions of figure 1.


** Cells transfected with the 2.4 kb fragment of gene MAGE-1 were tested for their ability to stimulate TNF release by CTL 82/30

03315559, 031797

APPROVED	C.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

12/13

FIG. 12



0819659.031797
25/TEO 6996T880

2627ED" 6996T880

APPROVED	C.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 13

